Abstract
The Framingham and other epidemiological studies have shown HDL and triglyceride to be inversely correlated. An independent relationship between HDL cholesterol and CAD was observed in other studies and also suggested by interventional trials. Decreased HDL-C and mildly elevated LDL-C are common in patients with coronary artery disease. Identification of receptors involved in the metabolism of HDL has been the subject of intensive research. The HDL particle may be recognized by different receptors in various tissues. Niacin and fibrate have a remarkable effect on the reduction of triglyceride and elevation of HDL, while their LDL lowering effect is moderate. Statins are effective and safe drugs for CHD, and exert beneficial effects across the lipoprotein profile. Therefore, the effects of statins on HDL-C may contribute to reductions in coronary events.
MeSH terms
-
Anticholesteremic Agents / pharmacology
-
Arteriosclerosis / blood
-
Arteriosclerosis / drug therapy
-
Arteriosclerosis / metabolism*
-
Arteriosclerosis / prevention & control*
-
Aryldialkylphosphatase
-
Atorvastatin
-
Cholesterol, HDL / blood
-
Cholesterol, HDL / metabolism*
-
Esterases / metabolism
-
Fatty Acids, Monounsaturated / pharmacology
-
Fluvastatin
-
Gemfibrozil / pharmacology
-
Heptanoic Acids / pharmacology
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
-
Hypolipidemic Agents / pharmacology*
-
Indoles / pharmacology
-
Lipid Peroxidation / drug effects
-
Lovastatin / pharmacology
-
Phosphatidylcholine-Sterol O-Acyltransferase / metabolism
-
Pyrroles / pharmacology
-
Simvastatin / pharmacology
Substances
-
Anticholesteremic Agents
-
Cholesterol, HDL
-
Fatty Acids, Monounsaturated
-
Heptanoic Acids
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hypolipidemic Agents
-
Indoles
-
Pyrroles
-
Fluvastatin
-
Lovastatin
-
Atorvastatin
-
Simvastatin
-
Phosphatidylcholine-Sterol O-Acyltransferase
-
Esterases
-
Aryldialkylphosphatase
-
Gemfibrozil